Translating complex biology is both an art and science. The founders of Verik know this from experience. In 2011, they recognized that the field of adoptive cell therapy could ultimately benefit from what they knew.

Previously, they were instrumental in establishing the field of tissue engineering, having pioneered the development of the first regulated living cell-based therapy in the US from an academic concept to market. The product, Apligraf® (Organogenesis Inc.), represents a yet unmatched scientific and medical achievement. Apligraf® remains both a first- and best-in-class therapy in wound healing after over twenty years in the real world–helping over a million patients.

Verik was founded to bring know-how acquired while working with normal biology and immunology to cancer biology. The knowledge and skills learned in tissue engineering provided a unique perspective that led to needed contributions in the T-cell targeting of epithelial cancers or carcinoma. This is evidenced by Verik’s expanding intellectual property of patented and patent-pending methods for discovery and T cell epitopes for solid tumor cancers.

Verik has called on seasoned veterans of biotech, pharma, and academics to expand our core competencies. Verik represents our continuing passion for science and its use in the creation of therapies that positively impact patient lives.